↓ Skip to main content

A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer

Overview of attention for article published in Journal for Immunotherapy of Cancer, June 2014
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (69th percentile)

Mentioned by

facebook
1 Facebook page
wikipedia
1 Wikipedia page

Citations

dimensions_citation
27 Dimensions

Readers on

mendeley
23 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer
Published in
Journal for Immunotherapy of Cancer, June 2014
DOI 10.1186/2051-1426-2-16
Pubmed ID
Authors

Paul LR Mitchell, Michael A Quinn, Peter T Grant, David G Allen, Thomas W Jobling, Shane C White, Anne Zhao, Vaios Karanikas, Hilary Vaughan, Geoffrey Pietersz, Ian FC McKenzie, Sharron E Gargosky, Bruce E Loveland

Abstract

Mucin 1 antigen, highly expressed by epithelial ovarian cancer (EOC), is a potential target for immunotherapy. A previous successful phase 1 trial was conducted in patients with adenocarcinoma who were injected with Cvac, autologous monocyte-derived dendritic cells (DCs) incubated with mannosylated mucin 1 protein (M-FP). The present study was a phase 2 trial of Cvac in patients with advanced EOC.

Mendeley readers

The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 23 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 4 17%
Other 3 13%
Unspecified 3 13%
Researcher 3 13%
Student > Ph. D. Student 3 13%
Other 4 17%
Unknown 3 13%
Readers by discipline Count As %
Medicine and Dentistry 6 26%
Unspecified 3 13%
Agricultural and Biological Sciences 3 13%
Immunology and Microbiology 2 9%
Biochemistry, Genetics and Molecular Biology 1 4%
Other 4 17%
Unknown 4 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 December 2017.
All research outputs
#3,481,876
of 12,440,396 outputs
Outputs from Journal for Immunotherapy of Cancer
#321
of 594 outputs
Outputs of similar age
#65,229
of 219,664 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#4
of 4 outputs
Altmetric has tracked 12,440,396 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 594 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.3. This one is in the 44th percentile – i.e., 44% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 219,664 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.